HER2+ SABCS 2024 Highlights

EP. 1: Overview of the DESTINY-Breast06 Study

ByRohit Gosain, MD,Rahul Gosain, MD,Sara Tolaney, MD, MPH

January 22nd 2025

Panelists discuss the results and implications of the DESTINY-Breast06 study, highlighting the efficacy of trastuzumab deruxtecan in patients with HER2-positive breast cancer previously treated with multiple lines of therapy.

EP. 2: Overview of the DESTINY-Breast12 Study

ByRohit Gosain, MD,Rahul Gosain, MD,Sara Tolaney, MD, MPH

January 22nd 2025

Panelists discuss the findings from the DESTINY-Breast12 study, focusing on the efficacy and safety of trastuzumab deruxtecan in patients with HER2-low breast cancer and its potential to expand treatment options for this subgroup.

EP. 3: Overview of the PATINA Study

ByRohit Gosain, MD,Rahul Gosain, MD,Sara Tolaney, MD, MPH

January 22nd 2025

Panelists discuss the PATINA study, examining the role of palbociclib in combination with letrozole as a first-line treatment for hormone receptor–positive, HER2-negative breast cancer, and its impact on progression-free survival.